June 27 (Bloomberg) -- Cadila Healthcare Ltd. a generic-drug maker based in Ahmedabad, India, was sued by Alpex Pharma SA for infringing a U.S. patent for the obesity drug Suprenza.
Alpex, based in Mezzovico, Switzerland, contends Cadila, doing business as Zydus Cadila, wrongly applied to the U.S. Food & Drug Administration to sell low-cost copies of the medicine before the patent expires in 2018, according to a lawsuit filed yesterday in federal court in Wilmington, Delaware.
Unless blocked by a judge, premature sales of the generic drug in the U.S. will cause “substantial and irreparable harm” to Alpex, the company said in court papers.
Sujatha Rajesh, a Cadila spokeswoman, didn’t immediately respond to an e-mailed request for comment on the lawsuit.
The case is Alpex v. Zydus, 13-cv-01143, U.S. District Court, District of Delaware (Wilmington).
To see the patent, click: 6,149,938.
To contact the reporter on this story: Phil Milford in Wilmington at email@example.com.
To contact the editor responsible for this story: Michael Hytha at firstname.lastname@example.org